Download full-text PDF |
Source |
---|
Proc Natl Acad Sci U S A
January 2025
Environmental Science & Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, MA 02134.
Wastewater receives per- and polyfluoroalkyl substances (PFAS) from diverse consumer and industrial sources, and discharges are known to be a concern for drinking water quality. The PFAS family includes thousands of potential chemical structures containing organofluorine moieties. Exposures to a few well-studied PFAS, mainly perfluoroalkyl acids (PFAA), have been associated with increased risk of many adverse health outcomes, prompting federal drinking water regulations for six compounds in 2024.
View Article and Find Full Text PDFOphthalmology
January 2025
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, USA. Electronic address:
Purpose: To evaluate the cost-utility of Luminopia and CureSight as therapy for amblyopia compared to current common amblyopic treatments such as glasses, atropine drops, and patching.
Design: Cost analysis based on data from published randomized control trials (RCTs).
Subjects: None; based on data from the Luminopia, CureSight and atropine RCTs.
Environ Sci Technol
January 2025
SKL-ESPC and SEPKL-AERM, College of Environmental Sciences and Engineering, and Center for Environment and Health, Peking University, Beijing 100871, P. R. China.
Anemia in women of reproductive age (WRA) presents a pressing global public health issue, particularly in low- and middle-income countries (LMICs). Yet, the potential impact of ozone (O) exposure on anemia remains uncertain. The study included 1,467,887 eligible women from 83 surveys of 45 LMICs between 2004 to 2020.
View Article and Find Full Text PDFEcol Evol
January 2025
Government of Alberta, Forestry and Parks Canmore Alberta Canada.
Objectives: The ETER701 trial demonstrated that benmelstobart combined with anlotinib and etoposide-carboplatin (EC) significantly extends survival in patients with extensive-stage small cell lung cancer (ES-SCLC), setting a new record for median overall survival. In contrast, anlotinib plus EC only significantly prolongs progression-free survival. However, there is currently no evidence evaluating the cost-effectiveness of these regimens as first-line treatments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!